Literature DB >> 18692977

A sensitive human bone assay for quantitation of tigecycline using LC/MS/MS.

Allena J Ji1, James P Saunders, Peter Amorusi, Nandan D Wadgaonkar, Kenneth O'Leary, Mauricio Leal, Gary Dukart, Bonnie Marshall, Eric N Fluhler.   

Abstract

Tigecycline (Tygacil,Wyeth) is a first-in-class, broad spectrum antibiotic with activity against multiple-resistant organisms. In order to address the unexpectedly low tigecycline concentrations in human bone samples analyzed using a LC/MS/MS method developed elsewhere, we have developed and validated a new and sensitive human bone assay for the quantitation of tigecycline using LC/MS/MS. The new method utilizes the addition of a stabilizing agent to the human bone sample, homogenization of human bone in a strong acidic-methanol extraction solvent, centrifugation of the bone suspension, separation by liquid chromatography, and detection of tigecycline by mass spectrometry. Linearity was demonstrated over the concentration range from 50 to 20,000 ng/g using a 0.1g human bone sample. The intra- and inter-day accuracy of the assay was within 100+/-15%, and the corresponding precision (CV) was <15%. The stability of tigecycline was evaluated and shown to be acceptable under the assay conditions. The extraction recovery of tigecycline with the current method was 79% when using radio-labeled rat bone samples as a substitute for human bone samples. Twenty-four human bone samples collected previously from volunteers without infections who had elective orthopedic surgery after receiving a single dose of tigecycline were re-analyzed using the current validated method. Tigecycline concentrations in these samples ranged from 238 to 794 ng/g with a mean value 9 times higher than the mean concentration previously reported. The data demonstrated that the current method has significantly higher extraction efficiency than the previously reported method.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18692977     DOI: 10.1016/j.jpba.2008.06.020

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  5 in total

1.  Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models.

Authors:  R Parra Millán; M E Jiménez Mejías; V Sánchez Encinales; R Ayerbe Algaba; A Gutiérrez Valencia; M E Pachón Ibáñez; C Díaz; J Pérez Del Palacio; L F López Cortés; J Pachón; Y Smani
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

2.  In Vivo Efficacy of a "Smart" Antimicrobial Implant Coating.

Authors:  Alexandra I Stavrakis; Suwei Zhu; Vishal Hegde; Amanda H Loftin; Alyssa G Ashbaugh; Jared A Niska; Lloyd S Miller; Tatiana Segura; Nicholas M Bernthal
Journal:  J Bone Joint Surg Am       Date:  2016-07-20       Impact factor: 5.284

Review 3.  Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

Authors:  Cornelia B Landersdorfer; Jürgen B Bulitta; Martina Kinzig; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  Concurrent Determination of Tigecycline, Tetracyclines and Their 4-Epimer Derivatives in Chicken Muscle Isolated from a Reversed-Phase Chromatography System Using Tandem Mass Spectrometry.

Authors:  Yawen Guo; Zhaoyuan He; Pengfei Gao; Shuyu Liu; Yali Zhu; Kaizhou Xie; Yuhao Dong
Journal:  Molecules       Date:  2022-09-20       Impact factor: 4.927

5.  Complex prosthetic joint infections due to carbapenemase-producing Klebsiella pneumoniae: a unique challenge in the era of untreatable infections.

Authors:  Jorgelina de Sanctis; Lucileia Teixeira; David van Duin; Camila Odio; Geraldine Hall; J Walton Tomford; Federico Perez; Susan D Rudin; Robert A Bonomo; Wael K Barsoum; Michael Joyce; Viktor Krebs; Steven Schmitt
Journal:  Int J Infect Dis       Date:  2014-05-09       Impact factor: 3.623

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.